Plain-English translation of NCT06730347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called in people with certain types of advanced gynecologic cancers — specifically platinum-resistant ovarian cancer and clear cell cancers of the ovary, uterus, cervix, vagina, vulva, fallopian tube, or peritoneum. The medication works by helping your immune system recognize and fight cancer cells. Researchers want to see if the treatment can slow or stop cancer growth and how safe it is.
Many people with these types of cancer stop responding to standard platinum-based chemotherapy, leaving few good treatment options. This medication is designed to work through the immune system in a new way that may help people whose cancers have become resistant to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through an IV) once every 3 weeks, for as long as the treatment is helping and side effects are manageable. You would visit the clinic for each infusion and have regular check-ins with physical exams and blood tests every cycle. Scans to check your tumor would happen approximately every 9 weeks in the first year, then every 12 weeks after that. The study continues until your cancer progresses, side effects become too difficult to manage, or you decide to stop.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States